New Singapore Rules Will Impact Drug Licensing, Trials, Surveillance
This article was originally published in PharmAsia News
Executive Summary
Pharmaceutical companies doing business in Singapore are being advised to review the procedures they have in place relating to drug licensing, conducting clinical trials and responding to post-market surveillance in light of proposed legislative changes in the country.